tasosartan angiotensin ii receptor antagonist withdrawn fda review manufacturer phase iii clinical trials showed elevated transaminases sign possible liver toxicity significant number participants given drug article relating cardiovascular system stub help wikipedia expanding httpsenwikipediaorgwikitasosartan